Vrinda Hershberger, MD
Retina Specialist · Melbourne, FLNPI 1770574642
Payments from drug & device makers
Across 908 payments — averaging $9014.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3.8M
- Roche TCRC, Inc.$1.6M
- Bayer$994K
- Eyepoint US, Inc.$777K
- Regeneron$683K
- AbbVie$111K
- plus $207K from 18 others
Across 14 payments — averaging $2066.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$15K
- Janssen Global Services, LLC$12K
- Regeneron$2K
What the payments were for
- Consulting fees$25,43265%
- Speaking & faculty fees$5,34914%
- Travel & lodging$4,35811%
- Food & beverage$4,16611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 260 | $3,809,196 |
| Roche TCRC, Inc. | 79 | $1,602,774 |
| Bayer | 191 | $994,247 |
| Eyepoint US, Inc. | 10 | $777,440 |
| Regeneron | 227 | $683,043 |
| AbbVie | 22 | $111,359 |
| Kyowa Kirin, Inc. | 36 | $93,065 |
| Astellas Pharma Global Development | 7 | $44,881 |
| Boehringer Ingelheim International GmbH | 3 | $43,969 |
| Janssen Global Services, LLC | 1 | $11,556 |
| F. Hoffmann-la Roche AG | 7 | $11,374 |
| Regeneron Healthcare Solutions, Inc. | 33 | $820 |
| Genentech USA, Inc. | 10 | $544 |
| Alcon | 2 | $166 |
| Rxsight Inc | 2 | $153 |
| Ocular Therapeutix, Inc. | 2 | $152 |
| Astellas Pharma US Inc | 5 | $147 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $85 |
| Amgen | 3 | $74 |
| Notal Vision, Inc. | 2 | $50 |
| Apellis Pharmaceuticals, Inc. | 2 | $43 |
| Oyster Point Pharma, Inc. | 1 | $28 |
| Harrow Eye, LLC | 1 | $26 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$9,939
- Non-Covered Product$9,254
- EYLEA$6,255
- EYP-1901$4,568
- VABYSMO$364
- RXSIGHT INJECTOR HANDPIECE$135
- RXSIGHT CONTACT LENS$135
- RXSIGHT INJECTOR CARTRIDGE$135
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$135
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$135
- LUMIGAN$125
- AcrySof IQ VIVITY IOL$121
- Lucentis$111
- YUTIQ$106
How this compares
$8,185,206 in reported general payments places this provider in the 95th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 19 | $2,787 |
| Prednisolone Acetate | 21 | $879 |
| ErythromycinErythromycin Base | 21 | $326 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Melbourne
- Peter BrachaMelbourne$33K
- Shailesh GuptaDeerfield Beach$18.8M
- Sunil GuptaPensacola$8.1M
- Stuart BurgessPlantation$4.6M
- Eduardo UchiyamaFt Lauderdale$4.1M
- Drew BawcombeDeerfield Beach$2M
- Dana DeupreeSpring Hill$1.5M
- Eric GuglielmoMerritt Island$1.5M
- Jason HandzaPinellas Park$1.3M
- Ashish SharmaFort Myers$994K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.